Aging, injuries, infections, and diseases are factors responsible for triggering neuroinflammation, which plays a crucial role in the development of neurodegenerative diseases
such as Alzheimer’s and Parkinson’s disease. Under normal physiological conditions, microglia and astrocytes protect neurons, but when activated by various factors, they can increase the release of pro-inflammatory molecules – cytokines and reactive oxygen species, leading to neuronal damage. In this process, inflammatory protein complexes called inflammasomes, which activate proteolytic enzymes known as caspases, are also important. Caspases, divided into inflammatory and apoptotic, are of key importance for triggering inflammatory responses and cell death. Caspase-1, one of the most studied caspases, triggers inflammation by activating cytokines IL-1β and IL-18 and cleaving gasdermin D, leading to a form of cell death called pyroptosis. Due to the importance of caspase-1 in inflammatory and apoptotic processes, there is potential for the use of caspase-1 inhibitors in the therapy of neurodegenerative diseases.
We synthesized analogues of literature-described reversible caspase-1 inhibitors, where aromatic fragments such as quinoxaline and quinoline bind to the S4 binding pocket. Various electrophilic warheads were attached to the aromatic scaffold via linkers, and their inhibition of human caspase-1’s was evaluated. Linkers, in most cases γ-aminobutyric acid combined with aminoethyl-N-methylamine, were firstly attached to the aromatic core. Various electrophilic warheads were then added onto the amine derivatives through amide bond formation, N-alkylation, and N-acylation. After confirming the identity and purity of the final compounds, the inhibitory potencies of 18 analogues against human caspase-1 were determined in a biochemical assay using a fluorogenic substrate. Five derivatives inhibited caspase-1, the most potent were
carbamoyl fluoride 25 (residual activity at 100 µM = 16.9%) and vinyl sulfonamide 34 (residual activity at 100 µM = 2.6%). The lack of inhibition for the majority of synthesized compounds can be explained by the distance of the linker connecting the electrophile and aromatic part of
the molecule, and the absence of an appropriate functional group for interactions with the S1 binding pocket, which would position the electrophilic centre near the catalytic Cys285.
|